Literature DB >> 18954300

Long-term donor outcomes after living kidney donation.

N D Soneji1, J Vyas, V E Papalois.   

Abstract

Kidney transplant is the first choice of treatment for end-stage renal failure. The issue of long-term donor safety again has been raised by recent increases in living-donor kidney transplants worldwide, relaxation of donor selection criteria, and the introduction of new surgical techniques. In this review, we collated the results of various studies to discuss the effects of donation on the quality of life of donors, encompassing their physical, mental, and social well-being. We found that the health risks donors face are minimal in the long term with respect to renal function, hypertension, and life span. Furthermore, donors scored higher in quality of life studies than did persons in the general population. Despite these findings, there is a clear need to monitor the minimal risks with long-term follow-up of donors to promptly recognize and treat any negative health effects. Such data from thorough follow-up studies also would provide accurate information on longterm donor health and improve the safe expansion of donor selection criteria.

Entities:  

Mesh:

Year:  2008        PMID: 18954300

Source DB:  PubMed          Journal:  Exp Clin Transplant        ISSN: 1304-0855            Impact factor:   0.945


  3 in total

1.  Regulated payments for living kidney donation: an empirical assessment of the ethical concerns.

Authors:  Scott D Halpern; Amelie Raz; Rachel Kohn; Michael Rey; David A Asch; Peter Reese
Journal:  Ann Intern Med       Date:  2010-03-16       Impact factor: 25.391

2.  Long-term, self-reported health outcomes in kidney donors.

Authors:  Käthe Meyer; Astrid Klopstad Wahl; Ida Torunn Bjørk; Torbjørn Wisløff; Anders Hartmann; Marit Helen Andersen
Journal:  BMC Nephrol       Date:  2016-01-12       Impact factor: 2.388

3.  Protocol for the Flinders Kidney Health Registry: patient outcomes of kidney cancers and nephrectomies.

Authors:  Jordan Y Li; Sarah Bodda; Alex Jay; Ganessan Kichenadasse; Michael Chong; Jonathan M Gleadle; Michael O'Callaghan
Journal:  BMC Urol       Date:  2022-07-21       Impact factor: 2.090

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.